Fabtech Technologies FY26: A Strong Order Book, A Reset Balance Sheet, and the Real Test on Cash Conversion

Fabtech Technologies Limited closed FY26 with a familiar message for a global turnkey engineering player: growth was healthy, execution was tested by external disruption, and the next leg depends on converting visibility into predictable cash flows. The company, positioned as a turnkey solutions provider for pharmaceutical, biotech, and healthcare facilities, reported consolidated total income of ₹431.33 crore for FY26, up 28.4% year on year. EBITDA rose 18.29% to ₹55.56 crore and operational PAT increased 17.4% to ₹36.6 crore. Reported FY26 net profit (PAT) was ₹38.36 crore.

What stood out as a structural change in FY26 was not only the top-line growth but the balance sheet shift. Cash and bank balances increased sharply to ₹208.57 crore from ₹35.01 crore, while total equity expanded to ₹419.77 crore from ₹173.11 crore. Management attributed this step-change to equity infusion during the year, describing it as capacity creation for the next phase of scale.

The business model: turnkey with in-house Process, Air and Water

Fabtech’s core positioning is built around a single-accountability turnkey approach for regulated life sciences infrastructure. In its investor presentation, the company argued that projects in pharma and biopharma increasingly require a partner that can integrate process systems, cleanroom environments, and purified water distribution under one ecosystem. The stated benefits include reduced coordination risk, faster delivery, and regulatory confidence for standards such as cGMP, WHO, EU-GMP, and USFDA.

Geographically, the company remains primarily international. It highlighted that 78% of revenue comes from MENA, GCC, and ECO Zone markets, with operations spanning 62 countries. Management also emphasized that GCC localization is now a strategic necessity and not optional, as on-ground presence improves execution, trust, and access in the region.

FY26 performance snapshot and the balance sheet reset

The financial disclosures in the presentation show growth but also point to a business where operational efficiency and cash discipline are becoming central themes.

A key nuance management highlighted on the call is comparability of profits. FY25 included an exceptional item (TSA) of ₹17.85 crore, while FY26 had ₹1.77 crore of exceptional items. Management encouraged investors to assess “operational” performance rather than the one-off swing in reported profits.

Operationally, management also highlighted the shift in operating cash flow from ₹(36.15) crore in FY25 to ₹0.48 crore in FY26 and the reduction in current borrowings from ₹54.09 crore to ₹42.20 crore.

Geography and execution: UAE, KSA, and a growing Africa corridor

Management provided select country-level revenue disclosures. UAE became the largest market in FY26, contributing ₹126.66 crore, followed by Saudi Arabia at ₹82.72 crore. Kenya was the fastest-growing disclosed geography, with revenue rising 236% YoY to ₹43.42 crore.

The company’s narrative places Africa as an increasingly important corridor, both for diversification and growth. Management framed this as risk mitigation as well, noting that diversification across 62-plus geographies is intended to balance disruptions in any one region.

At the same time, the Middle East remains central. The call repeatedly returned to the importance of localization in UAE and KSA, not as a branding exercise but as a practical response to execution constraints, including visas and the need to mobilize manpower locally during disruption.

Order book visibility and selected project wins

Fabtech reported a consolidated order book of ₹900+ crore as of March 31, 2026. Management described this as offering strong visibility and stated that the company intends to deliver this order book over the next 18 to 24 months.

The company also highlighted selected project wins across high-growth markets:

• West Africa OSD facility: USD 7.05 million (about ₹63.6 crore) with a 23 to 27 month execution timeline.
• Saudi Arabia animal vaccine project: USD 7.8 million (about ₹65.5 crore) with an 11 month timeline, covering turnkey cleanroom, HVAC, MEP, and utilities.
• North Africa next-generation veterinary facility: ₹49 to ₹52 crore, targeted completion by Q1 FY27, positioned as EU-GMP compliant and export enabling.

Management also discussed a strategy of increasing ticket sizes, referencing a shift from earlier order sizes of USD 30 to 40 million to projects approaching USD 70 million.

What pressured margins and what management says changes next

Investors pushed hard on margins and volatility during the Q&A. Management acknowledged cost pressures from logistics disruption, freight challenges, and remobilization of teams, including higher local hiring in markets like Saudi and UAE. Management also described a portfolio mix effect, with certain Africa projects carrying relatively lower margins.

Receivables were another key topic. The company disclosed total receivables of ₹204.34 crore and described receivable management as a strategic operational priority for the next four quarters. Management also shared that receivables in UAE were ₹37.10 crore and in KSA ₹61.38 crore, stating they largely reflect project scale and normal collection cycles, especially with last-quarter-heavy billing.

On cost escalation clauses, management said contracts include variation clauses and that discussions with clients are handled as sensible commercial conversations rather than disputes. However, management also clarified it does not frame it as simply passing costs to customers, but rather balancing project outcomes and long-term relationships.

Guidance and what to track in FY27

Management provided forward-looking guidance in the call:

• Top-line growth projection of approximately 25% ahead.
• PAT margin guidance of about 9.9% to 10.5%.

In Q&A, management also referenced internal targets around EBITDA margins of 13% to 14% and PAT margins of 9% to 11%.

A notable operational theme is the company’s effort to reduce lumpiness and increase predictability. Management emphasized that Fabtech is not a quarter-to-quarter story, pointing out that booking differs from billing and billing depends on client civil readiness and site acceptance. To improve control over timelines, management discussed bidding for broader scope including pre-engineered building structures and solar integration. The stated rationale is that controlling more of the project schedule can reduce cycle times and protect margins.

Takeaways

FY26 for Fabtech Technologies combined strong growth and a materially stronger balance sheet with clear operational watchpoints. The company has meaningful visibility via a ₹900+ crore order book and has disclosed traction in UAE, KSA, and Kenya. It also entered higher-potential segments such as animal health and vaccine-related facilities.

The near-term investor test is simpler than the strategy story: whether execution remains resilient in disrupted geographies, whether receivables convert into cash more consistently, and whether margins improve towards the guided band while scaling. If management delivers on collections discipline alongside the stated growth outlook, FY27 could be less about visibility and more about conversion.